Polpharma’s manufacturing activity is carried out mainly in Starogard Gdański, at GMP-compliant facilities. The company utilizes up-to-date technologies, which ensure the safety of products, employees, and the natural environment. Manufacturing processes comply with all the environmental protection requirements of the European Union.

Polpharma’s annual capacity is approximately 200 m drug packages. In one of the largest and most modern drug manufacturing plants in Europe, the company manufactures solid drug forms, such as tablets, film-coated tablets, effervescent tablets, sugar coated tablets and capsules. The annual manufacturing capacity of solid forms is 6 billion units. A fully hermetic manufacturing process allows for protection from any possible contamination and protects employees from contact with chemicals.

Polpharma also manufactures parenteral drugs, injectable preparations in polyethylene packagings and glass ampoules,  eye drops, nasal drops, infusion fluids and fluids for external use. In 2005, the company started manufacturing in the new ampoule filling facility, wich was constructed in compliance with the strictest cGMP standards for sterile manufacturing.

Besides for finished drug forms, Polpharma manufactures active pharmaceutical ingredients. The capacity of the company’s reactors is 320 000 liters. API manufacturing facilities are regularly audited by the FDA. Installations for the manufacturing of APIs and finished forms have GMP certificates that are issued by the Main Pharmaceutical Inspectorate. Polpharma also offers contract manufacturing services of both drug products and active pharmaceutical ingredients.